A vaccine given during pregnancy is dramatically reducing hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a decrease of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and passing protection through the placenta. A significant recent study examining nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the period when infants are particularly susceptible to the virus. RSV affects roughly 50 per cent of newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.
How the immunisation protects at-risk babies
RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects approximately half of all newborns in their first few months of life. The virus can vary from causing mild, cold-like symptoms to causing severe chest infections that cause babies to struggle to breathe and feed. In the most serious cases, the inflammation in the lungs becomes life-threatening, with small numbers of babies dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of serious RSV infections: “In babies with severe infections you can see their chest and lungs working hard, as they try to pull enough oxygen in. This is very, very frightening as a parent, frightening with good reason.”
The pregnancy vaccine works by stimulating the mother’s body’s defences to generate protective antibodies, which are then passed to the developing baby through the placenta. This mother-derived protection provides newborns with immediate protection from the moment of birth, exactly when they are highly susceptible to RSV. The latest research demonstrates that protection reaches approximately 85% when the vaccine is administered at least four weeks before delivery. Even briefer gaps between vaccination and birth can still provide substantial defence, with evidence indicating that a two-week gap is sufficient to shield babies born slightly early. Dr Watson recommends pregnant women to receive the vaccine on schedule, whilst noting that protection can still occur even if given later in the third trimester.
- Nearly 85% protection when vaccinated 4 weeks before birth
- Maternal antibodies passed through the placenta safeguard newborns from birth
- Coverage achievable with two-week gap before premature birth
- Vaccination in third trimester still provides meaningful protection for infants
Strong evidence from current research
The efficacy of the pregnancy RSV vaccine has been confirmed through a comprehensive study carried out throughout England, examining data from approximately 300,000 babies born between September 2024 and March 2025. This constitutes approximately nine out of ten of all births during that six-month timeframe, providing strong and reliable evidence of the vaccine’s practical effectiveness. The study’s findings have been validated by the UK Health Security Agency as showing robust protection for newborns during their most critical early weeks. The scale of this research provides healthcare professionals and parents-to-be with confidence in the vaccine’s established performance across varied populations and settings.
The results paint a notable picture of the vaccine’s ability to protect. More than 4,500 babies were hospitalised with RSV throughout the study period, with the great majority being infants whose mothers had not been given the vaccination. This marked difference emphasises the vaccine’s vital importance in preventing serious illness in newborns. The reduction in hospital admissions above 80 per cent represents a significant public health achievement, possibly preventing thousands of infants from experiencing the frightening and potentially life-threatening symptoms associated with severe RSV infection. These findings strengthen the importance of the vaccination programme introduced in the UK in 2024.
Study methodology and scope
The research examined birth and hospital admission records from England over a six-month timeframe, capturing data on approximately 90 per cent of all births during this timeframe. By examining nearly 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were in a position to determine direct comparisons of RSV infection levels and hospitalisations. The substantial sample size and comprehensive nature of the data gathering ensured that findings were statistically robust and indicative of the general population, rather than isolated cases or limited subgroups.
The study specifically monitored hospital admissions for RSV among infants born to mothers who had been given the vaccine at varying intervals before delivery. This allowed researchers to determine the minimum time required between vaccination and birth for maximum protection, as well as to determine whether protection remained meaningful with reduced timeperiods. The methodology measured practical outcomes rather than controlled laboratory conditions, providing practical evidence of how the vaccine works when given across different clinical contexts and patient circumstances throughout the third trimester of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Grasping RSV and the risks
Respiratory syncytial virus, typically known as RSV, is among the primary causes of hospital admission in infants under one year of age across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their first few months of life, with severity changing substantially from mild cold-like symptoms to serious, potentially fatal chest infections. More than 20,000 babies require serious hospital treatment for RSV annually in the UK alone, placing considerable pressure on paediatric wards and neonatal units during busier periods.
The infection triggers inflammation deep within the lungs and airways, making it dangerously difficult for vulnerable newborns to breathe and feed adequately. Parents commonly see their babies visibly struggling, their chests rising whilst they try to pull sufficient oxygen into their damaged lungs. Whilst most infants recover with palliative treatment, a small but significant number die from RSV complications yearly, making vaccination as prevention a essential public health objective for safeguarding the most vulnerable and youngest members of society.
- RSV produces inflammation in lungs, resulting in severe breathing difficulties in infants
- Approximately half of infants acquire the virus in their first few months of life
- Symptoms range from minor cold-like symptoms to life-threatening chest infections requiring hospitalisation
- More than 20,000 UK infants need serious hospital treatment for RSV annually
- A small number of infants succumb to RSV related complications annually in the UK
Take-up rates and expert recommendations
Since the RSV vaccine programme began in 2024, health officials have highlighted the significance of pregnant women receiving their jab at the optimal time for maximum protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has emphasised that timing matters greatly for ensuring newborns receive the maximum immunity from birth. Whilst the evidence indicates that vaccination performed at least four weeks prior to delivery delivers approximately 85% protection, experts encourage women to get their vaccine as soon as feasible from 28 weeks of pregnancy onwards to enhance the antibodies passed to their babies via the placenta.
The guidance from public health bodies stays clear: pregnant women ought to prioritise vaccination during their third trimester, even if circumstances mean they cannot get vaccinated at the optimal time. Dr Watson has reassured expectant mothers that protection remains still achievable with shorter intervals between vaccination and birth, including even a fourteen-day window for those giving birth ahead of schedule. This adaptable strategy recognises the practical demands of pregnancy whilst maintaining strong protection for at-risk infants during their most critical early months when RSV represents the highest danger of severe infection.
Regional differences in vaccination
Whilst the RSV vaccine programme has been launched across England, uptake rates and deployment schedules have varied across different regions and NHS trusts. Some areas have attained higher vaccination coverage among qualifying expectant mothers, whilst others remain focused to increase awareness and availability of the jab. These geographical variations reflect differences across medical facilities, communication strategies, and community involvement initiatives, though the national data shows consistently strong protection regardless of geographical location.
- NHS trusts launching varied communication campaigns to engage with pregnant women
- Geographic variations in immunisation take-up across England require targeted improvement
- Local healthcare systems modifying schemes to suit specific population needs
Real-world impact and parent viewpoints
The vaccine’s outstanding effectiveness provides concrete gains for families across the United Kingdom. With more than 20,000 babies hospitalised annually due to RSV prior to the launch of this protective measure, the 80% drop in admissions means thousands of infants protected against serious illness. Parents no more face the troubling prospect of seeing their babies gasping for air or labour to feed, symptoms that define serious RSV disease. The vaccine has substantially transformed the landscape of neonatal lung health, offering expectant mothers a proactive tool to shield their youngest infants during those critical early months.
For families like that of Malachi, whose severe RSV infection led to devastating brain damage, the vaccine’s introduction carries profound emotional significance. His mother’s promotion of the jab highlights the transformative consequences that preventable illness can inflict on young children and their families. Whilst Malachi’s experience predates the vaccine programme, his story resonates powerfully with parents now offered protection. The knowledge that such significant complications—hospital stay, oxygen dependency, neurological damage—are now mostly preventable has offered substantial reassurance to pregnant women in their third trimester, changing what was once an predictable seasonal threat into a controllable health concern.